Phase II Reactions: Acetylation Reactions

Acetylation is a phase II biotransformation reaction that adds an acetyl group to drugs or their metabolites. The nonmicrosomal enzyme N-acetyltransferase catalyzes this process using endogenous acetyl CoA derived from carbohydrate and fatty acid metabolism. This conjugation reaction resembles α-amino acid conjugation but uses exogenous amines as substrates instead.

Acetylation targets drugs and metabolites containing primary aliphatic and aromatic amines, hydrazines, and sulfonamides. Notable drugs metabolized through acetylation include isoniazid, procainamide, and sulfonamides. Additionally, acetylation plays a vital role in metabolizing neurotransmitters like catecholamines and hormones, extending its importance beyond xenobiotic metabolism.

Acetylation polymorphism is a genetic variation affecting N-acetyltransferase activity across individuals, creating fast and slow acetylators. This distinction significantly influences drug metabolism rates, efficacy, and toxicity levels. Genetic differences in acetyltransferase enzyme activity determine whether individuals rapidly or slowly metabolize acetylated drugs, impacting clinical outcomes.

Yes, acetylation can generate toxic metabolites with serious consequences. Isoniazid acetylation produces a tissue acylating intermediate causing liver toxicity. Additionally, arylacetamide acetylation induces liver damage. While acetylation typically deactivates xenobiotics, certain drug structures create harmful metabolites, making toxicity monitoring essential for acetylated drugs.

Acetyl CoA serves as the acylating agent in acetylation reactions, providing the acetyl group transferred to drug substrates. This endogenous cofactor is derived from carbohydrate and fatty acid metabolism, making it readily available for phase II conjugation. The N-acetyltransferase enzyme uses acetyl CoA to facilitate the addition of acetyl groups to susceptible functional groups.

Acetylation resembles α-amino acid conjugation because both add functional groups to drug molecules through enzymatic conjugation. However, acetylation uses exogenous amines as substrates and acetyl CoA as the conjugating agent, distinguishing it from other phase II reactions like glucuronidation or glutathione conjugation that employ different substrates and cofactors.

Acetylation results in either xenobiotic deactivation or synthesis of active metabolites, depending on the drug structure. This phase II process modifies drug properties to enhance elimination and reduce bioavailability. The reaction's outcome—whether producing inactive or active metabolites—significantly affects drug efficacy, duration of action, and potential adverse effects in patients.